Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 4, 2004, Pages 384-388

  Yaz, Gökçen ^a   Kabadere, Selda ^a   Öztopçu, Pinar ^c   Durmaz, Ramazan ^b   Uyar, Ruhi ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b Department of Neurosurgery ^*  (Turkey)

^c Faculty of Science and Literature   (Turkey)

Author keywords

Cell proliferation; Clomiphene; Glioma; MTT assay; Nafoxidine; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; CLOMIFENE; FORMAZAN; NAFOXIDINE; TAMOXIFEN; TETRAZOLIUM;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COUNT; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CLOMIPHENE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; GLIOMA; HUMANS; NAFOXIDINE; RATS; TAMOXIFEN; TUMOR STEM CELL ASSAY;

EID: 3843106184     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000071945.15623.C6     Document Type: Article

References (23)

1. Mastronardi L, Puzzilli F, Ruggeri A. Tamoxifen as a potential treatment of glioma. Anticancer Drugs 1998;9:581-6.
2. Puchner MJA, Giese A, Zapf S, et al. Tamoxifen sensitivity-testing of glioblastomas: comparison of in vitro and in vivo results. Acta Neurochir 2001;143:563-73.
3. Pasqualini JR, Sumida C, Giambiagi N. Pharmacodynamic and biological effects of antiestrogens in different models. J Steroid Biochem 1988;31:613-43.
4. Bloom HJG, Boesem E. Antiestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases. BMJ 1974;2:7-10.
5. Hayon T, Duilansky A, Oriev L, et al. Non-steroidal antiestrogens induce apoptosis in HL60 and MOLT3 leukemic cells; involvement of reactive oxygen radicals and protein kinase C. Anticancer Res 1999;19: 2089-93.
6. Kornblith P. Role of tissue culture in prediction of malignancy. Clin Neurosurg 1978;25:346-75.
7. Chen TT, Mealey J. Microculture of human brain tumors. Cancer Chemother Rep 1970;54:9-143.
8. Unterman TG, Click RP, Waites GT, et al. Production of insulin-like growth factor-binding proteins by human central nervous system tumors. Cancer Res 1991;51:3030-6.
9. Durmaz R, Deliorman S, Işiksoy S, et al. Antiproliferative properties of the Lazaroids U-83836E and U-74389G on glioma cells in vitro. Pathol Oncol Res 1999;5:223-8.
10. Mossmann T. Rapid colorimetric assay of cellular growth and survival: application to proliferation and cytotoxicity assay. J Immun Method 1983;65:55-63.
11. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a micro-culture tetrazolium assay. Cancer Res 1988;48:589-601.
12. Couldwell WT, Hinton DR, He S, et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell line. FEBS Lett 1994;345:43-6.
13. Heerdt AS, Borgen AI. Current status of tamoxifen use: an update for the surgical oncologists. J Surg Oncol 1999;72:42-9.
14. Zhang W, Couldwell WT, Song H, et al. Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. Cancer Res 2000;60:5395-400.
15. Malet C, Compel A, Spritzer P, et al. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 1988;48:7193-9.
16. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF-7 cells; correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982;42:317-23.
17. Bultuch GH, Couldwell WT, Willemure JG, et al. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cells. A comparison between staurosporine and tamoxifen. Neurosurgery 1993;33:495-501.
18. Puchner MA, Giese A. Tamoxifen-resistant glioma cell sub-populations are characterized by increased migration and proliferation. Int J Cancer 2000;86:468-73.
19. Toma S, Ugolini D, Palumbo P. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? Int J Oncol 1999;15:321-37.
20. McClay EF, Jones JA, Winski PJ, et al. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res 1996;56:3993-7.
21. Borg A, Baldetorp B, Ferno M, et al. erbB2 amplification is associated with tamoxifen resistance in steroid-receptor-positive breast cancer. Cancer Lett 1994;81:137-44.
22. Treon SP, Teoh G, Urashima M, et al. Antiestrogens induce apoptosis in multiple myeloma cells. Blood 1998;92:1749-57.
23. Giannakopoulou M, Bozas E, Philippidis H, et al. Protooncogene c-fos involvement in the molecular mechanism of rat brain sexual differentition. Neuroendocrinology 2001;73:387-96.